Arlington, Va. — New research being presented at the 2010 FIP Pharmaceutical Sciences World Congress in association with the American Association of Pharmaceutical Scientists Annual Meeting and Exposition will highlight a targeted inhalable dry powder vaccine that may prove preferable in terms of needle avoidance and expected lower cost than the current commercial human papillomavirus (HPV) vaccine used throughout the world.
HPV is the number one cause of cervical cancer, which is the second most common cancer in women around the globe. According to the World Health Organization, nearly a quarter of a million women die each year from cervical cancer, 80 percent of them in developing countries.
Lead researcher David McAdams and colleagues from the University of Colorado at Boulder created a dry powder that goes directly to the mucous membranes in the respiratory tract or mouth. Since HPV is a disease that affects the mucous membranes, the powder is more targeted. "Imagine the vaccine as a car," said McAdams. "Using this delivery method is similar to parking in your driveway instead of driving around the block a few times to find a spot."
The dry powder has added benefits for developing countries. For example, the current HPV vaccine is delivered by a needle injection, which is highly susceptible to contamination. The powder, as a solid, rather than a frozen liquid, may be more stable than current HPV vaccines, which makes it easier to store and transport in developing countries.
"While there are effective HPV vaccines on the market, cost, refrigeration and needle disposal shorten the reach they have," commented McAdams. "Our goal is to develop an economical, safe and easily administered HPV vaccine for everyone."
For the first time, FIP's PSWC and the AAPS Annual Meeting and Exposition will join to hold the world's largest pharmaceutical sciences meeting to improve global health through advances in pharmaceutical sciences. An estimated 10,000 scientists from more than 60 countries will participate in 100 sessions, including 40 symposia and roundtables.
Learn more about the meeting and global health from leading scientists in this webisode series and follow the tweet hashtag #PSWC2010 for meeting updates.
Editor's Note: All press must register and provide press credentials to attend this meeting. To register, please contact CatapanoJ@aaps.org or 703-248-4772. To schedule an interview with David McAdams or any other press inquiry, please contact Hillarie Turner at firstname.lastname@example.org or 202-296-2002 x113.
About AAPS: The American Association of Pharmaceutical Scientists is a professional, scientific society of approximately 12,000 members employed in academia, industry, government and other research institutes worldwide. For more information, please visit www.aapspharmaceutica.com.
About FIP: The International Pharmaceutical Federation is the global federation of national associations representing two million pharmacists and pharmaceutical scientists from around the world. For more information, please visit www.fip.org.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.